Department of Molecular Medicine, Aarhus University Hospital, Skejby, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark.
Expert Rev Mol Diagn. 2010 Jan;10(1):49-64. doi: 10.1586/erm.09.74.
Prostate cancer is the most commonly diagnosed malignancy in males in the Western world. This review focuses on advances in biomarker discovery for prostate cancer by microarray profiling of mRNA and microRNA expression. Novel biomarkers are strongly needed to enable more accurate detection of prostate cancer, improve prediction of tumor aggressiveness and facilitate discovery of new therapeutic targets for tailored medicine. Promising molecular markers identified from gene expression profiling studies include AMACR, EZH2, TMPRSS2-ERG, miR-221 and miR-141, which are described in more detail. In addition, a compilation of prognostic gene expression signatures for prediction of prostate cancer patient outcome is provided, and their possible clinical utility is discussed. Furthermore, limitations in the application of microarray-based expression profiling for identification of prostate cancer biomarkers are addressed.
前列腺癌是西方世界男性最常见的恶性肿瘤。本综述重点介绍了通过 mRNA 和 microRNA 表达的微阵列分析发现前列腺癌生物标志物的进展。需要新型生物标志物来更准确地检测前列腺癌，提高对肿瘤侵袭性的预测，并有助于发现新的治疗靶点，以实现个体化医疗。从基因表达谱研究中确定的有前途的分子标记物包括 AMACR、EZH2、TMPRSS2-ERG、miR-221 和 miR-141，对其进行了更详细的描述。此外，还提供了用于预测前列腺癌患者预后的预后基因表达特征的汇编，并讨论了它们的可能临床应用。此外，还讨论了基于微阵列的表达谱分析在鉴定前列腺癌生物标志物方面的应用限制。
